HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Continuous Hyperfractionated Accelerated Radiotherapy in Patients With Inoperable Non-Small-Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 1, 2008, Pages 132-138

  De Ruysscher, Dirk ^a,b   Wanders, Rinus ^b   van Haren, Erik ^c   Hochstenbag, Monique ^a   Geraedts, Wiel ^c   Pitz, Cordula ^d   Simons, Jean ^e   Boersma, Liesbeth ^b   Verschueren, Tom ^b   Minken, Andre ^b   Bentzen, Søren M ^f   Lambin, Philippe ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRO CLINIC   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d LAURENTIUS HOSPITAL   (Netherlands)

^e Maasland Hospital ^*  (Netherlands)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Dose escalation; HI CHART; NSCLC; Phase I II; Radiotherapy

Indexed keywords

DOSIMETRY; ONCOLOGY; PATIENT MONITORING; PULMONARY DISEASES; RISK ANALYSIS; THREE DIMENSIONAL;

DOSE ESCALATION; HI CHART; LOCAL TUMOR RECURRENCE; PHASE I/II;

RADIOTHERAPY;

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; PREDNISONE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS DISEASE; FEASIBILITY STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; ESOPHAGUS; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS;

EID: 41749106933     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.09.048     Document Type: Article

References (35)

1. Curran W., Scott C., Langer C., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. [Abstract]. Proc ASCO (2003) 2499
2. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
3. Saunders M.I., Dische S., Barrett A., et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multi-center trial. Radiother Oncol 52 (1999) 137-148
4. Sause W., Kolesar P., Taylor S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
5. Rosenzweig K.E., Mychalczak B., Fuks Z., et al. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J 6 (2000) 82-87
6. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy update of a phase I trial. J Clin Oncol 19 (2001) 127-136
7. Narayan S., Henning G.T., Ten Haken R.K., et al. Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer. Lung Cancer 44 (2004) 79-88
8. Socinski M.A., Morris D.E., Halle J.S., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: A dose-escalation phase I trial. J Clin Oncol 22 (2004) 4341-4350
9. Rosenman J.G., Halle J.S., Socinski M.A., et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54 (2002) 348-356
10. Kong F.M., Ten Haken R.K., Schipper M.J., et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 324-333
11. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
12. Thirion P., Holmberg O., Collins C.D., et al. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol 71 (2004) 163-166
13. Belderbos J., Heemsbergen W., De Jaeger K., et al. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 126-134
14. Saunders M.I., Rojas A., Lyn B.E., et al. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy week end less) in non-small cell lung cancer. Br J Cancer 78 (1998) 1323-1328
15. Saunders M.I., Rojas A., Lyn B.E., et al. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol 14 (2002) 352-360
16. Rojas A.M., Lyn B.E., Wilson E.M., et al. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer. Cancer 107 (2006) 1321-1330
17. Bentzen S.M., Saunders M.I., and Dische S. From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome. Clin Oncol (R Coll Radiol) 14 (2002) 372-381
18. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys 62 (2005) 988-994
19. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., et al. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases?. Eur J Nucl Med 25 (1998) 1495-1501
20. International Commission on Radiation Units and Measurements. ICRU report 50. Prescribing, recording, and reporting photon beam therapy (1993), Oxford University Press, Oxford
21. Schultheiss T.E. Spinal cord radiation tolerance. Int J Radiat Oncol Biol Phys 30 (1994) 735-736
22. Rampling R., and Symonds P. Radiation myelopathy. Curr Opin Neurol 11 (1998) 627-632
23. Philippens M.E., Pop L.A., Visser A.G., et al. Dose-volume effects in rat thoracolumbar spinal cord: An evaluation of NTCP models. Int J Radiat Oncol Biol Phys 60 (2004) 578-590
24. Bentzen S.M., Saunders M.I., and Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol 53 (1999) 219-226
25. Nijsten S.M., Mijnheer B.J., Dekker A.L., et al. Routine individualised patient dosimetry using electronic portal imaging devices. Radiother Oncol 83 (2007) 65-75
26. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
27. Green M.R., Cox J.D., Ardizzoni A., et al. Endpoints for multi-modal clinical trials in stage III non-small cell lung cancer (NSCLC): A consensus report. Lung Cancer 11 (1994) S11-S13
28. Rubin P., and Wasserman T.H. International clinical trials in radiation oncology: The late effects of toxicity scoring. Int J Radiat Oncol Biol Phys 114 (1988) S29-S38
29. Bentzen S.M., and Baumann M. The linear-quadratic model in clinical practice. In: Steel G.G. (Ed). Basic clinical radiobiology (2002), Arnold, London 134-146
30. Willner J., Baier K., Caragiani E., et al. Dose, volume, and tumor control prediction in primary radiotherapy of nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 52 (2002) 382-389
31. Mehta M., Scrimger R., Mackie R., et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 49 (2001) 23-33
32. Kelsey C.R., Kahn D., Hollis D.R., et al. Radiation-induced narrowing of the tracheobronchial tree: An in-depth analysis. Lung Cancer 52 (2006) 111-116
33. Timmerman R.D., Kavanagh B.D., Cho L.C., et al. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25 (2007) 947-952
34. Bosmans G., van Baardwijk A., Dekker A., et al. Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys 66 (2006) 748-753
35. Underberg R.W., Lagerwaard F.J., Slotman B.J., et al. Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: An analysis of 4DCT datasets. Int J Radiat Oncol Biol Phys 62 (2005) 554-560